AI Engines For more Details: Perplexity Kagi Labs You
Gut health: Gluco-oligosaccharides act as prebiotics, nourishing beneficial bacteria in the gut such as Bifidobacteria and Lactobacilli. By promoting the growth of these probiotic bacteria, gluco-oligosaccharides help maintain a healthy balance of gut flora, which is essential for digestion, nutrient absorption, and immune function. A healthy gut microbiota can help prevent gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD), and diarrhea.
Improved digestion: Gluco-oligosaccharides increase stool bulk and promote regular bowel movements, which can help alleviate symptoms of constipation and promote overall digestive health. By supporting bowel regularity, gluco-oligosaccharides may reduce the risk of colorectal cancer and other digestive disorders.
Immune support: Gluco-oligosaccharides have immunomodulatory properties and may help enhance the body's immune response. They stimulate the activity of immune cells such as macrophages, natural killer cells, and T cells, helping to strengthen the immune system's defense against infections and diseases. Gluco-oligosaccharides may be beneficial for individuals with weakened immune systems or recurrent infections.
Bone health: Some studies suggest that gluco-oligosaccharides may have beneficial effects on bone health. They have been shown to enhance calcium absorption and promote bone formation, which may help prevent osteoporosis and reduce the risk of fractures, especially in postmenopausal women who are at higher risk of bone loss.
Weight management: Gluco-oligosaccharides can contribute to feelings of fullness and satiety when consumed as part of a meal or snack. By delaying gastric emptying and increasing the release of satiety hormones, gluco-oligosaccharides may help control appetite and reduce calorie intake, which can support weight loss or weight management efforts.
Blood sugar control: Gluco-oligosaccharides may help regulate blood sugar levels by slowing down the absorption of carbohydrates in the intestines. This can help prevent rapid spikes in blood glucose levels after meals and improve insulin sensitivity, making it beneficial for individuals with diabetes or insulin resistance. Gluco-oligosaccharides may also contribute to feelings of fullness and satiety, which can aid in blood sugar control and weight management.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Increases |
genus | Saccharomyces | Increases |
species | Bifidobacterium adolescentis | Increases |
species | Bifidobacterium animalis | Increases |
species | Bifidobacterium bifidum | Increases |
species | Bifidobacterium breve | Increases |
species | Bifidobacterium catenulatum | Increases |
species | Bifidobacterium longum | Increases |
species | Bifidobacterium pseudocatenulatum | Increases |
species | Bifidobacterium pseudolongum | Increases |
species | Faecalibacterium prausnitzii | Reduces |
species | Lacticaseibacillus casei | Increases |
species | Lactiplantibacillus pentosus | Increases |
species | Lactiplantibacillus plantarum | Increases |
species | Lactobacillus acidophilus | Increases |
species | Lactobacillus crispatus | Increases |
species | Lactobacillus gasseri | Increases |
species | Lactobacillus helveticus | Increases |
species | Lactobacillus jensenii | Increases |
species | Lactobacillus johnsonii | Increases |
species | Lactobacillus kefiranofaciens | Increases |
species | Saccharomyces cerevisiae | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 1.4 | 1.4 | |
ADHD | 1.2 | 1.8 | -0.5 |
Age-Related Macular Degeneration and Glaucoma | 0.2 | -0.2 | |
Allergic Rhinitis (Hay Fever) | 2.3 | 1.1 | 1.09 |
Allergies | 2.1 | 3.8 | -0.81 |
Allergy to milk products | 1.3 | 0.1 | 12 |
Alzheimer's disease | 1.8 | 2.4 | -0.33 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 1.2 | -1.4 |
Ankylosing spondylitis | 1.4 | 0.6 | 1.33 |
Anorexia Nervosa | 0.6 | 1.6 | -1.67 |
Asthma | 2.1 | 2.7 | -0.29 |
Atherosclerosis | 1 | 1.7 | -0.7 |
Atrial fibrillation | 1.1 | 1.7 | -0.55 |
Autism | 4.3 | 2.9 | 0.48 |
Autoimmune Disease | 1.3 | 1.1 | 0.18 |
benign prostatic hyperplasia | 0.7 | -0.7 | |
Biofilm | 0.8 | -0.8 | |
Bipolar Disorder | 1 | 1.1 | -0.1 |
Brain Trauma | 1.2 | 1.6 | -0.33 |
Breast Cancer | 0.6 | -0.6 | |
Cancer (General) | 3.1 | 3.1 | |
Carcinoma | 0.6 | 0.6 | 0 |
Celiac Disease | 1.8 | 2.5 | -0.39 |
Cerebral Palsy | 1.1 | -1.1 | |
Chronic Fatigue Syndrome | 1.2 | 1.6 | -0.33 |
Chronic Kidney Disease | 0.8 | 1.1 | -0.38 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | -0.8 | |
Chronic Urticaria (Hives) | 1 | -1 | |
Cognitive Function | 1.9 | 1.3 | 0.46 |
Colorectal Cancer | 1.4 | 1.9 | -0.36 |
Constipation | 0.2 | 0.5 | -1.5 |
Coronary artery disease | 0.6 | 1 | -0.67 |
COVID-19 | 2.3 | 3.7 | -0.61 |
Crohn's Disease | 2.2 | 3.1 | -0.41 |
cystic fibrosis | 0.8 | 0.7 | 0.14 |
d-lactic acidosis (one form of brain fog) | 3 | -3 | |
deep vein thrombosis | 0.6 | 0.6 | |
Denture Wearers Oral Shifts | 0.6 | 0 | 0 |
Depression | 3.3 | 4.7 | -0.42 |
Dermatomyositis | 0.6 | 0.6 | |
Eczema | 2 | 0.1 | 19 |
Endometriosis | 1.9 | 1.2 | 0.58 |
Epilepsy | 2.2 | 1.1 | 1 |
erectile dysfunction | 0.6 | 0.2 | 2 |
Fibromyalgia | 1.2 | 2.2 | -0.83 |
Functional constipation / chronic idiopathic constipation | 2.1 | 1.6 | 0.31 |
gallstone disease (gsd) | 1.7 | 0.7 | 1.43 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.7 | |
Generalized anxiety disorder | 1.3 | 0.5 | 1.6 |
Glioblastoma | 0.7 | -0.7 | |
Gout | 0 | 0 | |
Graves' disease | 1.2 | 1.7 | -0.42 |
Gulf War Syndrome | 0.6 | 0 | 0 |
Hashimoto's thyroiditis | 1.4 | 1.6 | -0.14 |
Heart Failure | 1.7 | 1.6 | 0.06 |
High Histamine/low DAO | 0.6 | 1.7 | -1.83 |
hypercholesterolemia (High Cholesterol) | 0.6 | 0.5 | 0.2 |
hyperglycemia | 2.3 | 0.5 | 3.6 |
Hyperlipidemia (High Blood Fats) | 0.8 | 1.1 | -0.38 |
hypertension (High Blood Pressure | 2.1 | 3 | -0.43 |
Hypothyroidism | 0.8 | 0.7 | 0.14 |
Hypoxia | 1.2 | 1.2 | 0 |
IgA nephropathy (IgAN) | 1.2 | 1.2 | |
Inflammatory Bowel Disease | 2.9 | 2.2 | 0.32 |
Insomnia | 0.2 | 1.5 | -6.5 |
Intelligence | 0.2 | 0.6 | -2 |
Intracranial aneurysms | 1.4 | 0.5 | 1.8 |
Irritable Bowel Syndrome | 2.5 | 2.2 | 0.14 |
ischemic stroke | 2.7 | -2.7 | |
Liver Cirrhosis | 1.9 | 1.7 | 0.12 |
Long COVID | 3.1 | 2.6 | 0.19 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 0.7 | -0.7 | |
Mast Cell Issues / mastitis | 0.6 | 0.6 | |
ME/CFS with IBS | 0.6 | 1 | -0.67 |
ME/CFS without IBS | 0.6 | 0.6 | |
Menopause | 0.7 | 1.2 | -0.71 |
Metabolic Syndrome | 2.7 | 3.4 | -0.26 |
Mood Disorders | 3.8 | 4.5 | -0.18 |
multiple chemical sensitivity [MCS] | 1.1 | -1.1 | |
Multiple Sclerosis | 2.2 | 2.9 | -0.32 |
Multiple system atrophy (MSA) | 0.7 | 0.6 | 0.17 |
myasthenia gravis | 0.5 | 0.5 | 0 |
neuropathic pain | 1 | -1 | |
Neuropathy (all types) | 1.6 | -1.6 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.5 | -0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.1 | 1.8 | 0.17 |
NonCeliac Gluten Sensitivity | 1.4 | 1.1 | 0.27 |
Obesity | 4 | 2.9 | 0.38 |
obsessive-compulsive disorder | 1.7 | 0.5 | 2.4 |
Osteoarthritis | 0.7 | 1 | -0.43 |
Osteoporosis | 1.4 | 1.7 | -0.21 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 2.4 | 3.5 | -0.46 |
Polycystic ovary syndrome | 1.7 | 1.9 | -0.12 |
Postural orthostatic tachycardia syndrome | 0.6 | 0.6 | |
Premenstrual dysphoric disorder | 0.6 | -0.6 | |
primary biliary cholangitis | 1.3 | -1.3 | |
Primary sclerosing cholangitis | 1.6 | -1.6 | |
Psoriasis | 0.5 | 1.2 | -1.4 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.1 | 2.8 | -0.33 |
Rosacea | 1.2 | 1.1 | 0.09 |
Schizophrenia | 1.6 | 3.4 | -1.13 |
scoliosis | 0.2 | 0.2 | |
Sjögren syndrome | 1.8 | 1.2 | 0.5 |
Sleep Apnea | 0.2 | 1.1 | -4.5 |
Slow gastric motility / Gastroparesis | 1.2 | 1.2 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.6 | 0.17 |
Stress / posttraumatic stress disorder | 1.2 | 2.2 | -0.83 |
Systemic Lupus Erythematosus | 1.4 | 1.1 | 0.27 |
Tic Disorder | 1.3 | 1.3 | |
Tourette syndrome | 0.6 | 0.2 | 2 |
Type 1 Diabetes | 2.5 | 1.6 | 0.56 |
Type 2 Diabetes | 2 | 3.2 | -0.6 |
Ulcerative colitis | 3.3 | 3.6 | -0.09 |
Unhealthy Ageing | 1.4 | 1.1 | 0.27 |
Vitiligo | 0.6 | 0.6 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]